Hepatitis C virus-specific CD8+ T cell frequencies are associated with the responses of pegylated interferon-α and ribavirin combination therapy in patients with chronic hepatitis C virus infection

Hepatology Research

Volumn 41, Issue 1, 2011, Pages 30-38

  Tatsumi, Tomohide ^a   Takehara, Tetsuo ^a   Miyagi, Takuya ^a   Nakazuru, Shoichi ^b   Mita, Eiji ^b   Kanto, Tatsuya ^a   Hiramatsu, Naoki ^a   Hayashi, Norio ^a,c  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA NATIONAL HOSPITAL   (Japan)

^c KANSAI ROSAI HOSPITAL   (Japan)

Author keywords

Chronic hepatitis C; HCV specific CTL; IFN ELISPOT; Peg IFN ; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; CD8 ANTIGEN; CORE PROTEIN; GAMMA INTERFERON; NONSTRUCTURAL PROTEIN 3; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASSOCIATION; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL SPECIFICITY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

EID: 78650731385     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00734.x     Document Type: Article

References (23)

1. Kumada H, Okanoue T, Onji M et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res 2010; 40: 8-13.
2. Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol 2006; 41: 17-27.
3. Price DA, Klenerman P, Booth BL, Phillip RE, Sewell AL. Cytotoxic T lymphocytes, chemokines and antiviral immunity. Annu Rev Immunol 1999; 14: 207-32.
4. Gruener NH, Lechner F, Jung MC et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 2001; 75: 5550-8.
5. Wedemeyer H, He XS, Nascimbeni M et al. Impaired effector function hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 2002; 169: 3447-58.
6. Takaki A, Wiese M, Maertens G et al. Cellular immune responses persist, humoral responses decrease two decade after recovery from a single source outbreak of hepatitis C. Nat Med 2000; 6: 578-82.
7. Pilli M, Zerbini A, Penna A et al. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology 2007; 133: 1132-43.
8. Ishii S, Koziel MJ. Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol 2008; 128: 133-47.
9. Altman JD, Moss PAH, Goulder PJR et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274: 94-6.
10. Lalvani A, Brookes R, Hambleton S, Britton WJ, Hill AV, McMicheal AJ. Rapid effector function in CD8+ memory T cells. J Exp Med 1997; 186: 859-65.
11. Tatsumi T, Herrem CJ, Olson WC et al. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 2003; 63: 4481-9.
12. Oze T, Hiramatsu N, Yakushijin T et al. Pegylated interferon alpha-2b (Peg-IFN α-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN α-2b plus ribavirin. J Viral Hepat 2009; 16: 578-85.
13. Rehermann B, Chang KM, McHutchinson JG, Kokka R, Houghton M, Chisari FV. Quantitative analysis of the peripheral blood cytotoxic T lymphocytes response in patients with chronic hepatitis C virus infection. J Clin Invest 1996; 98: 1432-40.
14. Nelson DR, Marousis CG, Ohno T, Davis GL, Lau JY. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocytes activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology 1998; 28: 225-30.
15. Lohr HF, Schmitz D, Arenz M, Weyer S, Gerken G, Meyer zum Buschenfelde KH. The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies. J Hepatol 1999; 31: 407-15.
16. Caetano J, Martinho A, Paiva A, Pais B, Valente C, Luxo C. Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV. J Virol 2008; 82: 7567-77.
17. Fried MW, Schifman ML, Reddy KR et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Eng J Med 2002; 347: 975-82.
18. Freeman AJ, Marinos G, Ffrench RA, Lloyd AR. Intrahepatic and peripheral blood virus-specific cytotoxic T lymphocyte activity is associated with a response to combination IFN-α and ribavirin treatment among patients with chronic hepatitis C virus infection. J Viral Hepat 2005; 12: 125-9.
19. Barnes E, Harcourt G, Brown D et al. The dynamics of T-lymhocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology 2002; 36: 743-54.
20. Sato N, Hirohashi Y, Tsukahara T et al. Molecular pathological approaches to human tumor immunology. Pathol Int 2009; 59: 205-17.
21. Lechner W, Wong DK, Dubar PR et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191: 1499-512.
22. Tam RC, Pai B, Bard J et al. Ribavirin polarizes human T cell responses toward a type 1 cytokine profile. J Hepatol 1999; 30: 376-82.
23. He XS, Rehermann B, Lopez-Labradoe XL et al. Quantitative analysis of chronic hepatitis C virus-specific CD8+ T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci USA 1999; 96: 5692-7.